Predicting vascular risk in Type 1 diabetes: Stratification in a hospital based population in Scotland

Diabetic Medicine

Volumn 22, Issue 2, 2005, Pages 164-171

  McKnight, John ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Coronary heart disease; Macrovascular disease; Type 1 diabetes; Vascular risk

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; REGISTER; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; UNITED KINGDOM; VASCULAR DISEASE;

ADULT; AGED; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SCOTLAND;

EID: 13444291405     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01372.x     Document Type: Article

References (21)

1. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR et al. The British Diabetic Association Cohort Study I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16: 459-65.
2. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR et al. The British Diabetic Association Cohort Study II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16: 466-71.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl J Med 1996; 335: 1001-9.
5. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes. Edinburgh: SIGN, 2001: SIGN Publication 55.
6. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-8.
7. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-57.
8. Hawthorne VM, Lewis SJ, Chalmers J. The Royal College of Physicians of Edinburgh Diabetes Register. Health Bull 1889; 56: 468-75.
9. Royal College of Physicians of Edinburgh Diabetes Register Group. Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in Type 1 diabetes mellitus. Diabet Med 2000; 17: 782-91.
10. Kendrick S, Clarke J. The Scottish record linkage system. Health Bull 1993; 51: 72-79.
11. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and non-diabetic subjects. Diab Med 1999; 16: 219-27.
12. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387-388.
13. Isles C, Ramsay L, Wallis E, Haq I, Ritchie L. Whom to treat in primary prevention? Proc Roy Coll Phys Edinburgh 1999; 29: 16-25.
14. National Heart Foundation. Clinical guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109: 224-232.
15. British Hyperlipidaemia Association British Hypertension Society. British Cardiac Society & Joint British recommendations on prevention of coronary disease in clinical practice. Heart 1998; 80: S1-S29.
16. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. with members of the Task Force. Joint European Societies recommendations on prevention of coronary heart disease in clinical practice. Atherosclerosis 1998; 142: 199-270.
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
18. McCormack JP, Levine M, Rango RE. Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. Can Med Assoc J 1997; 157: 422-428.
19. Tunstall-Pedoe H. How cardiovascular risk varies with age, sex and coronary risk factors: do standard risk scores give an accurate perspective? Eur Heart J 1999 Suppl.: D25-D31.
20. Anonymous. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 1995; 48: 1441-52.
21. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 36: 2005-16.